du Bois A - Search Results

1

Topotecan versus treosulfan, an alkylating agent, in patients with epithelial ovarian cancer and relapse within 12 months following 1st-line platinum/paclitaxel chemotherapy. A prospectively randomized phase III trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group (AGO-OVAR).

Meier W, du Bois A, Reuss A, Kuhn W, Olbricht S, Gropp M, Richter B, Lück HJ, Kimmig R, Pfisterer J. Meier W, et al. Among authors: du bois a. Gynecol Oncol. 2009 Aug;114(2):199-205. doi: 10.1016/j.ygyno.2009.04.026. Epub 2009 May 14. Gynecol Oncol. 2009. PMID: 19446314 Clinical Trial.

2

Therapeutic strategies in cervical pregnancy.

Dall P, Pfisterer J, du Bois A, Wilhelm C, Pfleiderer A. Dall P, et al. Among authors: du bois a. Eur J Obstet Gynecol Reprod Biol. 1994 Sep;56(3):195-200. doi: 10.1016/0028-2243(94)90170-8. Eur J Obstet Gynecol Reprod Biol. 1994. PMID: 7821493 Review.

3

Comparison of the emetogenic potential between cisplatin and carboplatin in combination with alkylating agents.

du Bois A, Vach W, Thomssen C, Karck U, Madjar H, Prömpeler H, Meerpohl HG. du Bois A, et al. Acta Oncol. 1994;33(5):531-5. doi: 10.3109/02841869409083931. Acta Oncol. 1994. PMID: 7917367 Clinical Trial.

4

Cellular DNA content and survival in advanced ovarian carcinoma.

Pfisterer J, Kommoss F, Sauerbrei W, Renz H, du Bois A, Kiechle-Schwarz M, Pfleiderer A. Pfisterer J, et al. Among authors: du bois a. Cancer. 1994 Nov 1;74(9):2509-15. doi: 10.1002/1097-0142(19941101)74:9<2509::aid-cncr2820740919>3.0.co;2-f. Cancer. 1994. PMID: 7923008

5

Recurrent cytogenetic aberrations and loss of constitutional heterozygosity in ovarian carcinomas.

Kiechle-Schwarz M, Bauknecht T, Karck U, Kommoss F, du Bois A, Pfleiderer A. Kiechle-Schwarz M, et al. Among authors: du bois a. Gynecol Oncol. 1994 Nov;55(2):198-205. doi: 10.1006/gyno.1994.1277. Gynecol Oncol. 1994. PMID: 7959284

6

Phase II study of pirarubicin combined with cisplatin in recurrent ovarian cancer.

du Bois A, Meerpohl HG, Madjar H, Spinner D, Dall P, Pfisterer J, Bauknecht T. du Bois A, et al. J Cancer Res Clin Oncol. 1994;120(3):173-8. doi: 10.1007/BF01202198. J Cancer Res Clin Oncol. 1994. PMID: 8263015 Clinical Trial.

7

Paclitaxel-induced "recall" soft tissue ulcerations occurring at the site of previous subcutaneous administration of paclitaxel in low doses.

du Bois A, Kommoss FG, Pfisterer J, Lück HJ, Meerpohl HG. du Bois A, et al. Gynecol Oncol. 1996 Jan;60(1):94-6. doi: 10.1006/gyno.1996.0017. Gynecol Oncol. 1996. PMID: 8557235

8

Interim Analysis of a Phase II study of epirubicin and paclitaxel as first-line therapy in patients with metastatic breast cancer.

Luck HJ, Thomssen C, duBois A, Lisboa BW, Untch M, Kuhnle H, Konecny G, Janicke F, Meerpohl HG, Lindner C, Hecker D, Diergarten K. Luck HJ, et al. Semin Oncol. 1996 Feb;23(1 Suppl 1):33-6. Semin Oncol. 1996. PMID: 8629034 Clinical Trial.

9

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer.

Meerpohl HG, du Bois A, Kühnle H, Lück HJ, Kreienberg R, Möbus V, Bauknecht T, Köchli O, Bochtler H, Diergarten K, et al. Meerpohl HG, et al. Among authors: du bois a. Semin Oncol. 1995 Dec;22(6 Suppl 15):7-12. Semin Oncol. 1995. PMID: 8643973 Clinical Trial.

10

Paclitaxel combined with carboplatin in the first-line treatment of advanced ovarian cancer: a phase I trial.

Meerpohl HG, du Bois A, Luck HJ, Kühnle H, Möbus V, Kreienberg R, Bauknecht T, Köchli O, Bochtler H, Diergarten K. Meerpohl HG, et al. Among authors: du bois a. Semin Oncol. 1997 Feb;24(1 Suppl 2):S2-17-S2-22. Semin Oncol. 1997. PMID: 9045330 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

561 results

Search Page